Extension of 2013 agreement allows an additional 1.4 million people living with HIV to benefit from sublicensed generics of World Health Organization-recommended antiretroviral. Paris, 25 July 2017 — The Medicines Patent Pool (MPP) has signed an extension of its licensing agreement with biopharmaceutical company Bristol-Myers Squibb ...

Introduction Pursuant to a license negotiated by the Medicines Patent Pool (MPP) with ViiV Healthcare (ViiV), an important new antiretroviral medicine, dolutegravir (DTG), will soon be available via generic competition in all low- and lower-middle-income countries, and a significant number of upper-middle-income countries as well. DTG ...